• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Keen Vision Acquisition Corporation

    4/2/24 5:19:14 PM ET
    $KVAC
    Get the next $KVAC alert in real time by email
    SC 13G 1 ea0203151-sc13gkvc_keen.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO §240.13d-2

     

    KEEN VISION ACQUISITION CORPORATION

    (Name of Issuer)

     

    Ordinary Share, $0.0001 par value per share

    (Title of Class of Securities)

     

    G52443119

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1 (b)
       
    ☐ Rule 13d-1 (c)
       
    ☒ Rule 13d-1 (d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. G52443119 13G Page 2 of 9 Pages

     

    1

    NAME OF REPORTING PERSON

     

    KVC Sponsor LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware, US

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    4,416,075(1)

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    4,416,075(1)

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,416,075(1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    22.8%(2)

    12

    TYPE OF REPORTING PERSON*

     

    OO

     

    (1)

    Includes 3,737,500 founder shares and 678,575 ordinary shares included in the private placement units. Excludes 678,575 ordinary shares issuable upon the exercise of 678,575 private placement warrants.
       
    (2) Percentage is calculated based on 19,366,075 ordinary shares issued and outstanding as reported on the Annual Report on Form 10-K filed by the Issuer on March 29, 2024.

     

     

     

     

    CUSIP No. G52443119 13G Page 3 of 9 Pages

     

    1

    NAME OF REPORTING PERSON

     

    WONG, Kenneth K.C.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Canada  

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

     

    6

    SHARED VOTING POWER

     

    4,416,075(1)

    7

    SOLE DISPOSITIVE POWER

     

     

    8

    SHARED DISPOSITIVE POWER

     

    4,416,075(1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,416,075(1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    22.8%(2)

    12

    TYPE OF REPORTING PERSON*

     

    IN

     

    (1)

    Includes 3,737,500 founder shares and 678,575 ordinary shares included in the private placement units. Excludes 678,575 ordinary shares issuable upon the exercise of 678,575 private placement warrants.
       
    (2) Percentage is calculated based on 19,366,075 ordinary shares issued and outstanding as reported on the Annual Report on Form 10-K filed by the Issuer on March 29, 2024. 

     

     

     

     

    CUSIP No. G52443119 13G Page 4 of 9 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Jason Wong

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Hong Kong  

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

     

    6

    SHARED VOTING POWER

     

    4,416,075(1)

    7

    SOLE DISPOSITIVE POWER

     

     

    8

    SHARED DISPOSITIVE POWER

     

    4,416,075(1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,416,075(1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    22.8%(2)

    12

    TYPE OF REPORTING PERSON*

     

    IN

     

    (1)

    Includes 3,737,500 founder shares and 678,575 ordinary shares included in the private placement units. Excludes 678,575 ordinary shares issuable upon the exercise of 678,575 private placement warrants
       
    (2) Percentage is calculated based on 19,366,075 ordinary shares issued and outstanding as reported on the Annual Report on Form 10-K filed by the Issuer on March 29, 2024. 

     

     

     

     

    CUSIP No. G52443119 13G Page 5 of 9 Pages

     

    Item 1.

     

      (a) Name of Issuer: Keen Vision Acquisition Corporation
         
      (b) Address of Issuer’s Principal Executive Offices: 37 Greenbriar Drive, Summit, New Jersey 07901

     

    Item 2.

     

      (a) Name of Person Filing:

     

    KVC Sponsor LLC

    WONG, Kenneth K.C.

    Jason Wong

     

      (b) Address of Principal Business Office or if none, Residence:

     

    KVC Sponsor LLC:

    c/o Keen Vision Acquisition Corporation

    37 Greenbriar Drive, Summit, New Jersey 07901

     

    WONG, Kenneth K.C.:

    c/o Keen Vision Acquisition Corporation

    37 Greenbriar Drive, Summit, New Jersey 07901

     

    Jason Wong

    c/o Keen Vision Acquisition Corporation

    37 Greenbriar Drive, Summit, New Jersey 07901 

     

      (c) Citizenship:

     

    KVC Sponsor LLC – Delaware, US

    WONG, Kenneth K.C. – Canada

    Jason Wong – Hong Kong  

     

      (d)

    Title of Class of Securities:

     

    Ordinary Share, $0.0001 par value per share

     

      (e) CUSIP Number: G52443119

     

    Item 3. Not Applicable

     

    Item 4. Ownership.

     

      (a) Amount Beneficially Owned:

     

    KVC Sponsor LLC – 4,416,075

     

    WONG, Kenneth K.C. – 4,416,075

     

    Jason Wong – 4,416,075

     

    KVC Sponsor LLC, the Issuer’s Sponsor, is the record holder of the securities reported herein. KVC Sponsor LLC is controlled by Mr. Kenneth Wong and Mr. Jason Wong, its managers. By virtue of this relationship, Mr. Kenneth Wong and Mr. Jason Wong may be deemed to share beneficial ownership of the securities held of record by our sponsor.

     

     

     

     

    CUSIP No. G52443119 13G Page 6 of 9 Pages

     

      (b) Percent of Class:

     

    KVC Sponsor LLC: 22.8%

     

    WONG, Kenneth K.C.: 22.8%

     

    Jason Wong: 22.8%

     

    The foregoing percentage is calculated based on 19,366,075 ordinary shares issued and outstanding as reported on the Annual Report on Form 10-K filed by the Issuer on March 29, 2024. 

     

      (c)

    Number of shares as to which such person has:

     

    KVC Sponsor LLC:

     

      (i) sole power to vote or to direct the vote: 4,416,075
         
      (ii) shared power to vote or to direct the vote: 0
         
      (iii) sole power to dispose or to direct the disposition of: 4,416,075
         
      (iv) shared power to dispose or to direct the disposition of: 0

     

        WONG, Kenneth K.C.:

     

      (i) sole power to vote or to direct the vote: 0
         
      (ii) shared power to vote or to direct the vote: 4,416,075
         
      (iii) sole power to dispose or to direct the disposition of: 0
         
      (iv) shared power to dispose or to direct the disposition of: 4,416,075

     

        Jason Wong:

     

      (i) sole power to vote or to direct the vote: 0
         
      (ii) shared power to vote or to direct the vote: 4,416,075
         
      (iii) sole power to dispose or to direct the disposition of: 0
         
      (iv) shared power to dispose or to direct the disposition of: 4,416,075

     

     

     

     

    CUSIP No. G52443119 13G Page 7 of 9 Pages

     

    Item 5.

    Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following: Not Applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person: Not Applicable

     

    Item 7. Identification and Classification of Subsidiary Which Acquired the Securities: Not Applicable

     

    Item 8. Identification and Classification of Members of the Group: Not Applicable

     

    Item 9. Notice of Dissolution of Group: Not Applicable

     

    Item 10.

    Certifications:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. G52443119 13G Page 8 of 9 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    April 2, 2024

     

      KVC SPONSOR LLC
         
      By /s/ WONG, Kenneth K.C.
      Name:  WONG, Kenneth K.C.
      Title: Manager
         
      WONG, KENNETH K.C.
         
      By /s/ WONG, Kenneth K.C.
      Name: WONG, Kenneth K.C.
         
      Jason Wong
         
      By /s/ Jason Wong
      Name: Jason Wong

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, Provided, however, That a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

     

     

     

    CUSIP No. G52443119 13G Page 9 of 9 Pages

     

    EXHIBIT 1

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the ordinary shares, $0.0001 par value per share, of Keen Vision Acquisition Corporation, a Delaware corporation, and further agree that this Joint Filing Agreement shall be included as an Exhibit to such joint filings.

     

    The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

     

    This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument.

     

    IN WITNESS WHEREOF, the undersigned have executed this agreement as of April 2, 2024.

     

      KVC SPONSOR LLC
         
      By /s/ WONG, Kenneth K.C.
      Name:  WONG, Kenneth K.C.
      Title: Manager
         
      WONG, KENNETH K.C.
         
      /s/ WONG, Kenneth K.C.  
      WONG, Kenneth K.C.  
         
      Jason Wong
         
      /s/ Jason Wong  
      Jason Wong  

     

     

     

     

     

    Get the next $KVAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KVAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KVAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit

      BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that updated results from its ongoing MUSIC-HFpEF Phase 1/2a clinical trial investigating SRD-002, a one-time gene therapy treatment delivered through a proprietary minimally invasive intracoronary infusion methodology, were presented at the 2025 HFpEF Summit held March 19-21, 2025, in Beverly Hills, CA. Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per year. Heart failure with preserved ejection fraction (HFp

      4/1/25 8:00:00 AM ET
      $KVAC
    • Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction

      BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on cardiovascular diseases with high unmet need by developing a range of next-generation therapeutics, today announced that the independent Data and Safety Monitoring Board (DSMB) has completed its planned review of the MUSIC-HFrEF Phase 1b/2 clinical trial data, recommending the completion of the Phase 1b portion and clearance to initiate the Phase 2 portion of the trial evaluating the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction (HFrEF). HFrEF is a prevalent form of heart disease that accounts for half of an estimated 64.3

      3/20/25 8:00:00 AM ET
      $KVAC
    • Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction

      BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics, today announced that patient dosing has been completed in its MUSIC-HFrEF Phase 1/2a clinical trial of the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction (HErEF). HErEF is a prevalent form of heart disease that accounts for half of an estimated 64.3 million heart failure cases worldwide and is currently considered a mass market incurable disease. The MUSIC-HFrEF trial is an open-label, uncontrolled st

      3/11/25 9:09:44 AM ET
      $KVAC

    $KVAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Keen Vision Acquisition Corporation

      SC 13G - Keen Vision Acquisition Corp. (0001889983) (Subject)

      11/14/24 9:07:56 PM ET
      $KVAC
    • SEC Form SC 13G filed by Keen Vision Acquisition Corporation

      SC 13G - Keen Vision Acquisition Corp. (0001889983) (Subject)

      11/14/24 6:03:06 PM ET
      $KVAC
    • Amendment: SEC Form SC 13G/A filed by Keen Vision Acquisition Corporation

      SC 13G/A - Keen Vision Acquisition Corp. (0001889983) (Subject)

      11/12/24 4:07:50 PM ET
      $KVAC

    $KVAC
    SEC Filings

    See more
    • SEC Form 10-Q filed by Keen Vision Acquisition Corporation

      10-Q - Keen Vision Acquisition Corp. (0001889983) (Filer)

      5/14/25 4:00:41 PM ET
      $KVAC
    • Amendment: SEC Form SCHEDULE 13G/A filed by Keen Vision Acquisition Corporation

      SCHEDULE 13G/A - Keen Vision Acquisition Corp. (0001889983) (Subject)

      5/13/25 6:36:16 AM ET
      $KVAC
    • SEC Form SCHEDULE 13G filed by Keen Vision Acquisition Corporation

      SCHEDULE 13G - Keen Vision Acquisition Corp. (0001889983) (Subject)

      5/1/25 4:43:49 PM ET
      $KVAC